Titan Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for a Phase 1 study of its six-month or longer subdermal formulation of nalmefene, an opioid antagonist, intended for the prevention of relapse following opioid detoxification in adults with Opioid Use Disorder.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.98 USD | -0.14% | +0.58% | -15.39% |
1st Jan change | Capi. | |
---|---|---|
-15.39% | 6.38M | |
+52.93% | 803B | |
+40.98% | 629B | |
-7.08% | 351B | |
+17.40% | 324B | |
+10.58% | 303B | |
+16.42% | 244B | |
+2.17% | 226B | |
+10.66% | 215B | |
+6.24% | 164B |
- Stock Market
- Equities
- TTNP Stock
- News Titan Pharmaceuticals, Inc.
- Titan Pharmaceuticals, Inc. Announces Fda Clearance of Ind Application for Nalmefene Implant